Literature DB >> 10483596

Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).

S D Canfield1, E A Simoes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10483596     DOI： 10.3928/0090-4481-19990801-08

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN： 0090-4481            Impact factor:   1.132


× No keyword cloud information.
  4 in total

1.  Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Authors:  Mark J C Nuijten; Wolfgang Wittenberg; Maximilian Lebmeier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

3.  Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.

Authors:  Pingsheng Wu; Gabriel J Escobar; Tebeb Gebretsadik; Kecia N Carroll; Sherian X Li; Eileen M Walsh; Edward F Mitchel; Chantel Sloan; William D Dupont; Chang Yu; Jeffrey R Horner; Tina V Hartert
Journal:  Am J Epidemiol       Date:  2018-07-01       Impact factor: 4.897

4.  Cost effectiveness of palivizumab in Spain: an analysis using observational data.

Authors:  Mark J Nuijten; Wolfgang Wittenberg
Journal:  Eur J Health Econ       Date:  2009-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.